Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 17/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15548450 | 0.92 | ELANE (0.65) | ELANELMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL12618370 | 0.92 | ELANE (0.65) | ELANELMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL16239664 | 0.89 | ELANE (0.67) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL7286193 | 0.87 | ELANE (0.65) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL5715531 | 0.87 | ELANE (0.65) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL15548022 | 0.87 | ELANE (0.66) | ELANELMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL15548052 | 0.87 | ELANE (0.59) | ELANELMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL19335427 | 0.86 | ELANE (0.62) | ELANELMNAMAPTNPSR1ALDH1A1 | |
| SCHEMBL28370638 | 0.86 | ELANE (0.62) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL10483702 | 0.86 | ELANE (1.00) | ELANELMNAMAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220071898-A1 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS | INSIGNIS THERAPEUTICS INC (US) | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071898-A1 | DIPIVEFRIN ORALLY DISINTEGRATING TABLET FORMULATIONS | ADGRF1, DDR1, AGER | ELANE 1564/4885LMNA 2725/4885MAPT 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.